On April 13, 2021, the FDA and CDC recommended a pause in the use of the Johnson & Johnson (Janssen) vaccine to investigate cases of cerebral venous sinus thrombosis in combination with low levels of blood platelets. As of April 23, 2021, the FDA and CDC recommended resuming the use of the vaccine as the “known and potential benefits outweigh its known and potential risks.” Women less than 50 years old should be notified of “the rare but increased risk of this adverse event and that there are other COVID-19 vaccine options available for which this risk has not been seen.”
For more information, please review the Knowledge Center’s updated Vaccine Clinical Evidence Document. Additional information is available from the FDA. General COVID-19 vaccine information is available from the CDC.